Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 6, 2004, Pages 795-807

  Chan, Kam Ming ^a   Jones, Robert L ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AFP 07; Arterial smooth muscle; Cicaprost; ONO AE1 259; Partial agonist; Prostacyclin analogues; Prostanoid receptors; Sulprostone; Taprostene

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 17,20 DIMETHYL DELTA6,6A CARBAPROSTAGLANDIN I2; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; 7,7 DIFLUORO 16,20 DIMETHYL 18,19 DIDEHYDROPROSTAGLANDIN I2; 9BETA CHLORO 19,20 DIDEHYDRO 9,15 DIDEOXY 16 HYDROXY 17,17 TRIMETHYLENEPROSTAGLANDIN E2; ACETYLCHOLINE; AFP 07; CICAPROST; ISOPRENALINE; ONO AEI 259; PHENYLEPHRINE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; PROSTANOID RECEPTOR; TAPROSTENE; TEI 9063; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD VESSEL TONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GUINEA PIG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SAPHENOUS VEIN; SMOOTH MUSCLE RELAXATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; GUINEA PIGS; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN; SPECIES SPECIFICITY; VASODILATION;

EID: 2542480876     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200406000-00009     Document Type: Article

References (51)

1. Wise H, Jones RL. An introduction to prostacyclin and its receptors. In: Prostacyclin and its Receptors. New York: Kluwer Academic; 2000:1-27.
2. Flohé L, Bohlke H, Frankus E, et al. Designing prostacyclin analogues. Drug Res. 1983;33:1240-1248.
3. Schneider J, Friderichs E, Kögel B, et al. Taprostene sodium. Cardiovasc Drug Rev. 1993;11:479-500.
4. Wise H, Jones RL. IP-receptors in the vasculature. In: Prostacyclin and its Receptors. New York: Kluwer Academic; 2000:137-188.
5. Sitbon O, Humbert M, Simmoneau G. Primary pulmonary hypertension: Current therapy. Prog Cardiovasc Dis. 2002;45:115-128.
6. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002;26:194-201.
7. 1 receptors in pig and rabbit blood vessels. Br J Pharmacol. 2001;134:313-324.
8. Chang CS, Negishi M, Nakano T, et al. 7,7- Difluoroprostacyclin derivative, AFP-07, a highly selective and potent agonist for the prostacyclin receptor. Prostaglandins. 1997;53:83-90.
9. Negishi M, Hashimoto H, Yatsunami K, et al. TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells. Prostaglandins. 1991;42:225-237.
10. Sturzebecher S, Haberey M, Muller B, et al. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins. 1986;31:95-109.
11. Coleman RA, Grix SP, Head SA, et al. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins. 1994;47:151-168.
12. Jones RL, Shum WWC, Gurney AM. Synergism between prostanoids and other vasoactive agents. J Card Surg. 2002;17:436-438.
13. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000;1483:285-293.
14. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122:217-224.
15. 4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000;141:1554-1559.
16. Cao J, Shayibuzhati M, Tajima T, et al. In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. Eur J Pharmacol. 2002;442:115-123.
17. 3-receptor in guinea-pig aorta: partial agonist action of the nonprostanoid ONO-AP-324. Br J Pharmacol. 1998;125:1288-1296.
18. 3 receptor. Prostaglandins Leukot Essent Fatty Acids. 1993;49:939-943.
19. Lawrence RA, Jones RL, Wilson NH. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and 1 on the guinea-pig ileum. Br J Pharmacol. 1992;105:271-278.
20. Whittle BJ, Moncada S, Mullane K, et al. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins. 1983;25:205-223.
21. 2 receptors. Prostaglandins. 1983;25:13-28.
22. 2 (DP) receptors: estimation of affinities and relative efficacies for a series of novel bicyclic ligands. With an appendix on goodness-of-fit analyses. Br J Pharmacol. 1992;106:996-1003.
23. Giles H, Leff P, Bolofo ML, et al. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol. 1989;96:291-300.
24. Pöch G, Holzmann S. Quantitative estimation of overadditive and under-additive drug effects by means of theoretical, additive dose-response curves. J Pharmacol Methods. 1980;4:179-188.
25. Ariens EJ, Van Rossum JM, Simonis AM. A theoretical basis of molecular pharmacology. Part III: interaction of one or two compounds with two independent receptor systems. Arzneim-Forsch. 1956;6:737-746.
26. rd Edition). Boston: Allyn and Bacon; 1995:444-481.
27. 2 antagonist and analgesic. Bioorg Med Chem Lett. 1994;4:509-514.
28. 2 blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989;97:783-794.
29. Lydford SJ, McKechnie KCW, Leff P. Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein. Prostaglandins. 1996;52:125-139.
30. Jones RL, Qian YM, Wise H, et al. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997;29:525-535.
31. Russell A, Watts S. Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther. 2000;294:598-604.
32. Lydford SJ, McKechnie KC, Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol. 1996;117:13-20.
33. 4 antagonist. Br J Pharmacol. 2003;138:P84.
34. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
35. 4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol. 1996;50:1031-1037.
36. 1 and IP receptors. Br J Pharmacol. 2000;131:601-609.
37. Karibe H, Hara A, Yuhki K-O, et al. Characterization of the prostanoid receptors participating in contraction or relaxation of the aorta using mice lacking the prostanoid receptors. Pharmacologist. 2002;44(Suppl 1): A81.
38. Durocher Y, Perret S, Thibaudeau E, et al. A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal Biochem. 2000;284:316-326.
39. 3-receptor agonists on rat femoral artery. Pharmacologist. 2002;44(Suppl 1):A81.
40. rd Edition). Philadelphia: Lippincott-Raven Publishers; 1997:289-330.
41. Michel G, Seipp U. In vitro studies with the stabilized epoprostenol analogue taprostene. Effect on platelets and erythrocytes. Drug Res. 1990;40:817-822.
42. Lew MJ. Extended concentration-response curves used to reflect full agonist efficacies and receptor-occupancy-response coupling ranges. Br J Pharmacol. 1995;115:745-752.
43. Corsini A, Folco GC, Fumagalli R, et al. (5Z)-carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol. 1987;90:255-261.
44. Armstrong RA, Lawrence RA, Jones RL, et al. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br J Pharmacol. 1989;97:657-668.
45. Seiler S, Brassard CL, Arnold AJ, et al. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther. 1990;255:1021-1026.
46. Merritt JE, Brown AM, Bund S, et al. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. Br J Pharmacol. 1991;102:260-266.
47. Chow KB, Wong YH, Wise H. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. Br J Pharmacol. 2001;134:1375-1384.
48. 2 analogues. In: Pike JE, Morton DR, eds. Advances in Prostaglandin. Thromboxane and Leukotriene Research. New York: Raven Press; 1985:393-425.
49. Watanabe Y, Matsumura K, Takechi H, et al. A novel subtype of prostacyclin receptor in the central nervous system. J Neurochem. 1999;72:2583-2592.
50. Vane JR. Inhibition of prostaglandin synthesis as mechanism of action for aspirin-like drugs. Nature. 1971;231:232-235.
51. Bley KR, Hunter JC, Eglen RM, et al. The role of IP prostanoid receptors in inflammatory pain. Trends Pharmacol Sci. 1998;19:141-147.